Liminatus Pharma
LIMN
14 hedge funds and large institutions have $254K invested in Liminatus Pharma in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
31% more capital invested
Capital invested by funds: $193K → $254K (+$60.3K)
27% more funds holding
Funds holding: 11 → 14 (+3)
3.58% more ownership
Funds ownership: 1.17% → 4.75% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$324K |
| 2 |
CCA
Cygnus Capital Advisors
Atlanta,
Georgia
|
+$187K |
| 3 |
Jane Street
New York
|
+$38K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$28.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$18.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$21.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$720 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$27 |
| 4 |
FFA
Farther Finance Advisors
San Francisco,
California
|
-$27 |
LIMN Hedge Fund Activity: Q1 2026 in Review
14 of the 8,198 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma (LIMN) for Q1 2026, worth a combined $254K — up 31% from $193K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LIMN positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $324K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $21.5K sold.
- 14 institutional investors held Liminatus Pharma (LIMN) as of Q1 2026, up from 11 in Q4 2025.
- Funds reported $254K of Liminatus Pharma stock for Q1 2026, up 31% quarter-over-quarter.
- 7 funds opened new Liminatus Pharma positions in Q1 2026 and 3 closed out, a net change of +4 holders.
- The largest Liminatus Pharma buyer in Q1 2026 was Citadel Advisors, an estimated $324K added.
- The largest Liminatus Pharma seller in Q1 2026 was Two Sigma Investments, an estimated $21.5K sold.
Based on aggregated 13F filings for Q1 2026.